Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.

Area of Science:

• Immunology
• Regenerative Medicine
• Infectious Diseases

Background:

• The emergence of SARS-CoV-2 has led to the COVID-19 pandemic, with no proven specific treatments.
• Severe cases of COVID-19 can result in cytokine storm, ARDS, multiple organ dysfunction, and death.
• Mesenchymal stem cells (MSCs) possess immunomodulatory properties beneficial for treating inflammatory conditions.

Purpose of the Study:

• To review the clinical outcomes of MSCs therapy in ARDS patients.
• To discuss the potential application of MSCs for treating COVID-19 patients.
• To address key issues related to MSCs use during the COVID-19 outbreak.

Main Methods:

• Literature review of preclinical and clinical studies involving MSCs for ARDS.
• Analysis of existing data on MSCs therapy for respiratory failure.
• Discussion of MSCs application in the context of the COVID-19 pandemic.

Main Results:

• Previous studies indicate MSCs therapy is safe and effective for ARDS and respiratory failure.
• The immunomodulatory effects of MSCs suggest potential therapeutic benefits for COVID-19.
• Further research and clinical application are warranted to establish MSCs efficacy in COVID-19.

Conclusions:

• MSCs therapy holds significant potential as an effective treatment for COVID-19, particularly for managing ARDS and cytokine storm.
• The established safety and efficacy of MSCs in ARDS provide a strong rationale for their use in COVID-19.
• Careful consideration of application and ongoing research are crucial for optimizing MSCs therapy during the pandemic.